PRESS RELEASE

Q2 2023 — Press release

Q2 2023PDF · 24 pages1.2 MB
FOR IMMEDIATE RELEASE
• 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and
adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%*
• Earnings per share (EPS) of $1.96 increasing 8.9% and adjusted EPS of $2.80 increasing by 8.1%*
• Company is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding
COVID-19 Vaccine and adjusted operational EPS
• Johnson & Johnson intends to "split off" Kenvue shares through an exchange offer as the form of its
next step in the separation, subject to market conditions
New Brunswick, N.J. (July 20, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for second-
quarter 2023. “Our robust performance in the second quarter and first half of 2023 is a testament to the hard work
and commitment of our colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief
Executive Officer. “We are entering the back half of the year from a position of strength with numerous catalysts,
including becoming a two-sector company focused on Pharmaceutical and MedTech innovation.”
OVERALL FINANCIAL RESULTS
Q2
($ in Millions, except EPS) 2023 2022 % Change
Reported Sales $25,530 $24,020 6.3%
Net Earnings/(Loss) $5,144 $4,814 6.9%
EPS (diluted) $1.96 $1.80 8.9%
Q2
Non-GAAP* ($ in Millions, except EPS) 2023 2022 % Change
Operational Sales1,2 7.5%
Adjusted Operational Sales1,3 6.2%
Adjusted Net Earnings1,4 $7,358 $6,912 6.5%
Adjusted EPS (diluted)1,4 $2.80 $2.59 8.1%
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
Note: values may have been rounded

-- 1 of 24 --

REGIONAL SALES RESULTS
Q2 % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
U.S. $13,444 $12,197 10.2% 10.2 - 8.0
International 12,086 11,823 2.2 4.7 (2.5) 4.4
Worldwide $25,530 $24,020 6.3% 7.5 (1.2) 6.2
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded
SEGMENT SALES RESULTS
Q2 % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
Consumer Health $4,011 $3,805 5.4% 7.7 (2.3) 7.7
Pharmaceutical 13,731 13,317 3.1 3.8 (0.7) 3.9
MedTech 7,788 6,898 12.9 14.7 (1.8) 9.9
Worldwide $25,530 $24,020 6.3% 7.5 (1.2) 6.2
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded

-- 2 of 24 --

SECOND QUARTER 2023 SEGMENT COMMENTARY:
Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and
translational currency.
Pharmaceutical
Pharmaceutical worldwide adjusted operational sales grew 3.9%*. Excluding the COVID-19 Vaccine, adjusted
operational sales grew 6.2%*. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), and
CARVYKTI (ciltacabtagene autoleucel) in Oncology, STELARA (ustekinumab) and TREMFYA (guselkumab) in
Immunology, UPTRAVI (selexipag) and OPSUMIT (macitentan) in Pulmonary Hypertension, and SPRAVATO
(esketamine) in Neuroscience. Growth was partially offset by ZYTIGA (abiraterone acetate) and IMBRUVICA
(ibrutinib) in Oncology, COVID-19 Vaccine (Ad26.COV2.S) in Infectious Diseases, and REMICADE (infliximab) in
Immunology.
MedTech
MedTech worldwide adjusted operational sales grew 9.9%*, driven primarily by electrophysiology products in
Interventional Solutions, trauma in Orthopaedics, wound closure products in General Surgery, biosurgery in
Advanced Surgery, and contact lenses in Vision. MedTech worldwide operational sales grew 14.7%*, with the
acquisition of Abiomed contributing 4.8%.
Consumer Health
Consumer Health worldwide adjusted operational sales increased 7.7%* largely driven by over-the-counter (OTC)
products. Major contributors to growth in OTC were TYLENOL and MOTRIN analgesics, upper respiratory products,
international smoking cessation products, and IMODIUM in digestive health products. Additional contributors to
growth were NEUTROGENA in Skin Health/Beauty products and Women’s Health products outside the United
States.
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports
on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news
releases and information available in the Investors section of the company’s website at news releases, as well as
www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com.

-- 3 of 24 --

Regulatory
Janssen Marks First Approval Worldwide for AKEEGA (Niraparib and Abiraterone Acetate
Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic
Castration Resistant Prostate Cancer with BRCA1/2 Mutations
Press
Release
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under
Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and
Atrial Fibrillation
Press
Release
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational
Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients
with Pulmonary Arterial Hypertension (PAH)
Press
Release
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval
of CARVYKTI for the Earlier Treatment of Patients with Relapsed or Refractory Multiple
Myeloma
Press
Release
Data
Release
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti-PD-1
Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-
Invasive Bladder Cancer
Press
Release
First Phase 3 TREMFYA (guselkumab) Data in Inflammatory Bowel Disease Show Positive
Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
Press
Release
New Data Published on Biosense Webster QDOT MICRO Catheter – the Latest
Advancement in Focal RF Ablation for Treating AFib
Press
Release
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at
ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated
Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
Press
Release
New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at
High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Press
Release
Janssen Announces Positive Topline Results for JNJ-2113—a Novel, First and Only Oral IL-
23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis1
Press
Release
Treatment with RYBREVANT (amivantamab-vmjw) Plus Chemotherapy Resulted in
Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival
in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell
Lung Cancer1
Press
Release
Other
Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow Press
Release
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine
Group to Develop Next Generation CAR-T Therapies
Press
Release
1 Subsequent to the quarter

-- 4 of 24 --

FULL-YEAR 2023 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company
is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These
items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
($ in Billions, except EPS) July 2023 April 2023
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point 6.0% – 7.0% / 6.5% 4.5% – 5.5% / 5.0%
Operational Sales2,5/ Mid-point
Change vs. Prior Year / Mid-point
$99.3B – $100.3B / $99.8B
7.0% – 8.0% / 7.5%
$97.9B – $98.9B / $98.4B
5.5% – 6.5% / 6.0%
Estimated Reported Sales3,5/ Mid-point
Change vs. Prior Year / Mid-point
$98.8B – $99.8B / $99.3B
6.5% – 7.5% / 7.0%
$97.9B – $98.9B / $98.4B
5.5% – 6.5% / 6.0%
Adjusted Operational EPS (Diluted)2,4/ Mid-point
Change vs. Prior Year / Mid-point
$10.60 – $10.70 / $10.65
4.5% – 5.5% / 5.0%
$10.50 – $10.60 / $10.55
3.5% – 4.5% / 4.0%
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
$10.70 – $10.80 / $10.75
5.5% – 6.5% / 6.0%
$10.60 – $10.70 / $10.65
4.5% – 5.5% / 5.0%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: July 2023 = $1.09 and April 2023 = $1.10 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
5 Excludes COVID-19 Vaccine
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by
visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the
live webcast in the Investors section of the company's website at events-and-presentations.

-- 5 of 24 --

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of
life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our
reach and size for good. We strive to improve access and affordability, create healthier communities, and put a
healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and
ingenuity to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth”
excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net
earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding
after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be
considered replacements for, and should be read together with, the most comparable GAAP financial measures.
Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investors section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional
information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of
selected compounds in late stage development and a copy of today’s earnings call presentation can also be found
in the Investors section of the company's website at quarterly results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act
of 1995 regarding, among other things: future operating and financial performance, product development, market
position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The
reader is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency
exchange rate fluctuations; competition, including technological advances, new products and patents attained by

-- 6 of 24 --

competitors; challenges inherent in new product research and development, including uncertainty of clinical success
and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including
restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays,
internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory
action; significant adverse litigation or government action, including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost
containment; changes in behavior and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the
separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to
successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the
separation; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company.
A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s
Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned
“Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s
subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson
does not undertake to update any forward-looking statement as a result of new information or future events or
developments.
Press Contacts: Investor Contacts:
Tesia Williams Jessica Moore
media-relations@its.jnj.com investor-relations@its.jnj.com

-- 7 of 24 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,787	$ 	1,687 	6.0 % 	6.0 	- 	3,522	$ 	3,244 	8.6 % 	8.6 	-
International 	2,224 	2,118 	5.0 	9.0 	(4.0) 	4,341 	4,147 	4.7 	10.1 	(5.4)
4,011 	3,805 	5.4 	7.7 	(2.3) 	7,863 	7,391 	6.4 	9.5 	(3.1)
Pharmaceutical (1)
U.S. 	7,818 	7,159 	9.2 	9.2 	- 	14,841 	13,791 	7.6 	7.6 	-
International 	5,913 	6,158 	(4.0) 	(2.5) 	(1.5) 	12,303 	12,395 	(0.7) 	3.1 	(3.8)
13,731 	13,317 	3.1 	3.8 	(0.7) 	27,144 	26,186 	3.7 	5.5 	(1.8)
Pharmaceutical excluding COVID-19 Vaccine (1)
U.S. 	7,818 	7,114 	9.9 	9.9 	- 	14,841 	13,671 	8.6 	8.6 	-
International 	5,628 	5,659 	(0.5) 	1.5 	(2.0) 	11,271 	11,514 	(2.1) 	1.9 	(4.0)
13,446 	12,773 	5.3 	6.2 	(0.9) 	26,112 	25,185 	3.7 	5.5 	(1.8)
MedTech (1)
U.S. 	3,839 	3,351 	14.6 	14.6 	- 	7,598 	6,576 	15.5 	15.5 	-
International 	3,949 	3,547 	11.3 	14.7 	(3.4) 	7,671 	7,293 	5.2 	10.3 	(5.1)
7,788 	6,898 	12.9 	14.7 	(1.8) 	15,269 	13,869 	10.1 	12.8 	(2.7)
U.S. 	13,444 	12,197 	10.2 	10.2 	- 	25,961 	23,611 	10.0 	10.0 	-
International 	12,086 	11,823 	2.2 	4.7 	(2.5) 	24,315 	23,835 	2.0 	6.5 	(4.5)
Worldwide 	25,530 	24,020 	6.3 	7.5 	(1.2) 	50,276 	47,446 	6.0 	8.2 	(2.2)
U.S. 	13,444 	12,152 	10.6 	10.6 	- 	25,961 	23,491 	10.5 	10.5 	-
International 	11,801 	11,324 	4.2 	7.0 	(2.8) 	23,283 	22,954 	1.4 	6.1 	(4.7)
Worldwide excluding COVID-19 Vaccine (1)	
25,245	$ 	23,476 	7.5 % 	8.9 	(1.4) 	49,244	$ 	46,445 	6.0 % 	8.3 	(2.3)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule
SECOND QUARTER 	SIX MONTHS
Percent Change

-- 8 of 24 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	13,444	$ 	12,197 	10.2 % 	10.2 	- 	25,961	$ 	23,611 	10.0 % 	10.0 	-
Europe 	5,894 	6,085 	(3.1) 	(3.9) 	0.8 	12,226 	12,109 	1.0 	3.0 	(2.0)
Western Hemisphere excluding U.S. 	1,713 	1,536 	11.5 	17.7 	(6.2) 	3,300 	3,018 	9.3 	16.1 	(6.8)
Asia-Pacific, Africa 	4,479 	4,202 	6.6 	12.5 	(5.9) 	8,789 	8,708 	0.9 	8.2 	(7.3)
International 	12,086 	11,823 	2.2 	4.7 	(2.5) 	24,315 	23,835 	2.0 	6.5 	(4.5)
Worldwide 	25,530	$ 	24,020 	6.3 % 	7.5 	(1.2) 	50,276	$ 	47,446 	6.0 % 	8.2 	(2.2)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
SECOND QUARTER 	SIX MONTHS
Percent Change

-- 9 of 24 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	25,530	$ 	100.0 	24,020	$ 	100.0 	6.3
Cost of products sold 	8,212 	32.2 	7,919 	33.0 	3.7
Gross Profit 	17,318 	67.8 	16,101 	67.0 	7.6
Selling, marketing and administrative expenses 	6,665 	26.1 	6,226 	25.9 	7.1
Research and development expense 	3,829 	15.0 	3,703 	15.4 	3.4
Interest (income) expense, net 	(23) 	(0.1) 	(26) 	(0.1)
Other (income) expense, net* 	(60) 	(0.2) 	273 	1.1
Restructuring 	145 	0.5 	85 	0.4
Earnings before provision for taxes on income 	6,762 	26.5 	5,840 	24.3 	15.8
Provision for taxes on income 	1,618 	6.4 	1,026 	4.3 	57.7
Net earnings 	5,144	$ 	20.1 	4,814	$ 	20.0 	6.9
Net earnings per share (Diluted) 	1.96	$ 	1.80	$ 	8.9
Average shares outstanding (Diluted) 	2,625.7 	2,667.9
Effective tax rate 	23.9 % 	17.6 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	8,824	$ 	34.6 	8,171	$ 	34.0 	8.0
Net earnings 	7,358	$ 	28.8 	6,912	$ 	28.8 	6.5
Net earnings per share (Diluted) 	2.80	$ 	2.59	$ 	8.1
Effective tax rate 	16.6 % 	15.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SECOND QUARTER
2023 	2022
* Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public
offering on May 8, 2023 through the end of the fiscal second quarter.

-- 10 of 24 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	50,276	$ 	100.0 	47,446	$ 	100.0 	6.0
Cost of products sold 	16,607 	33.0 	15,517 	32.7 	7.0
Gross Profit 	33,669 	67.0 	31,929 	67.3 	5.4
Selling, marketing and administrative expenses 	12,803 	25.5 	12,164 	25.6 	5.3
Research and development expense 	7,392 	14.7 	7,165 	15.1 	3.2
In-process research and development 	49 	0.1 	610 	1.3
Interest (income) expense, net 	(43) 	(0.1) 	(38) 	(0.1)
Other (income) expense, net* 	7,168 	14.3 	171 	0.4
Restructuring 	275 	0.5 	155 	0.3
Earnings before provision for taxes on income 	6,025 	12.0 	11,702 	24.7 	(48.5)
Provision for taxes on income 	949 	1.9 	1,739 	3.7 	(45.4)
Net earnings 	5,076	$ 	10.1 	9,963	$ 	21.0 	(49.1)
Net earnings per share (Diluted) 	1.93	$ 	3.73	$ 	(48.3)
Average shares outstanding (Diluted) 	2,630.7 	2,669.2
Effective tax rate 	15.8 % 	14.9 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	17,292	$ 	34.4 	16,389	$ 	34.5 	5.5
Net earnings 	14,426	$ 	28.7 	14,041	$ 	29.6 	2.7
Net earnings per share (Diluted) 	5.48	$ 	5.26	$ 	4.2
Effective tax rate 	16.6 % 	14.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SIX MONTHS
2023 	2022
* Fiscal six months Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public
offering on May 8, 2023 through the end of the fiscal second quarter.

-- 11 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2023 	2022 	2023 	2022
$5,144 	$4,814 	$5,076 	$9,963
137 	385 	7,037 	385
1,211 	1,095 	2,415 	2,203
165 	276 	609 	276
282 	268 	582 	370
145 	128 	275 	200
85 	70 	149 	130
38 	- 	80 	-
(1) 	109 	71 	520
- 	- 	49 	610
- 	- 	- 	(7)
(373) 	(313) 	(2,430) 	(706)
546 	2 	557 	98
(21) 	78 	(44) 	(1)
$7,358 	$6,912 	$14,426 	$14,041
2,625.7 	2,667.9 	2,630.7 	2,669.2
$2.80 	$2.59 	$5.48 	$5.26
Net Earnings, after tax- as reported
Pre-tax Adjustments
Litigation related
Intangible Asset Amortization expense
COVID-19 Vaccine related costs 1
Consumer Health separation costs
Restructuring related 2
Medical Device Regulation 3
Acquisition, integration and divestiture related
(Gains)/losses on securities
IPR&D
Other
Tax Adjustments
Tax impact on special item adjustments 4
Consumer Health separation tax related costs
Tax legislation and other tax related
Adjusted Net Earnings, after tax
Average shares outstanding (Diluted)
Adjusted net earnings per share (Diluted)
Operational adjusted net earnings per share (Diluted) $2.84 	$5.59
Notes:
1
2
3
4
Second Quarter 	Six Months Ended
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses,
associated with the Company's completion of its COVID-19 vaccine contractual commitments.
In the first and second quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the Pharmaceutical segment to focus
on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are
primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The
restructuring expenses of $145 million in the quarter ($275 million Q2 YTD) include the termination of partnered and non-partnered program costs and asset impairments.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted
earnings.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the
existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning
in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has
excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and
assessing performance which is expected to be completed during 2024.

-- 12 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	MedTech 	Total
WW As Reported 	5.4% 	3.1% 	12.9% 	6.3%
U.S. 	6.0% 	9.2% 	14.6% 	10.2%
International 	5.0% 	(4.0)% 	11.3% 	2.2%
WW Currency 	(2.3) 	(0.7) 	(1.8) 	(1.2)
U.S. 	- 	- 	- 	-
International 	(4.0) 	(1.5) 	(3.4) 	(2.5)
WW Operational 	7.7% 	3.8% 	14.7% 	7.5%
U.S. 	6.0% 	9.2% 	14.6% 	10.2%
International 	9.0% 	(2.5)% 	14.7% 	4.7%
Abiomed 	(4.8) 	(1.4)
U.S. 	(8.1) 	(2.2)
International 	(1.7) 	(0.5)
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.0 	0.1
U.S. 	0.0 	0.0 	0.0 	0.0
International 	0.0 	0.3 	0.0 	0.2
WW Adjusted Operational 	7.7% 	3.9% 	9.9% 	6.2%
U.S. 	6.0% 	9.2% 	6.5% 	8.0%
International 	9.0% 	(2.2)% 	13.0% 	4.4%
Adjusted Operational Sales Growth
SECOND QUARTER 2023 ACTUAL vs. 2022 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	MedTech 	Total
WW As Reported 	6.4% 	3.7% 	10.1% 	6.0%
U.S. 	8.6% 	7.6% 	15.5% 	10.0%
International 	4.7% 	(0.7)% 	5.2% 	2.0%
WW Currency 	(3.1) 	(1.8) 	(2.7) 	(2.2)
U.S. 	- 	- 	- 	-
International 	(5.4) 	(3.8) 	(5.1) 	(4.5)
WW Operational 	9.5% 	5.5% 	12.8% 	8.2%
U.S. 	8.6% 	7.6% 	15.5% 	10.0%
International 	10.1% 	3.1% 	10.3% 	6.5%
Abiomed 	(4.7) 	(1.4)
U.S. 	(8.2) 	(2.3)
International 	(1.6) 	(0.5)
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.0 	0.1
U.S. 	0.0 	0.0 	0.0 	0.0
International 	0.0 	0.3 	0.0 	0.2
WW Adjusted Operational 	9.5% 	5.6% 	8.1% 	6.9%
U.S. 	8.6% 	7.6% 	7.3% 	7.7%
International 	10.1% 	3.4% 	8.7% 	6.2%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2023 ACTUAL vs. 2022 ACTUAL
Segments

-- 14 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 Reported Operational (1) Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	712	$ 	663 	7.5% 	7.5% 	- 	1,457	$ 	1,333 9.3% 	9.3% 	-
Intl 	947 	818 	15.7% 	19.0% 	-3.3% 	1,844 	1,609 14.6% 	19.4% -4.8%
WW 	1,659 	1,482 	12.0% 	13.9% 	-1.9% 	3,301 	2,943 12.2% 	14.8% -2.6%
SKIN HEALTH / BEAUTY
US 	650 	629 	3.4% 	3.4% 	- 	1,267 	1,173 8.0% 	8.0% 	-
Intl 	498 	497 	0.3% 	3.8% 	-3.5% 	991 	965 2.7% 	8.1% -5.4%
WW 	1,148 	1,126 	2.0% 	3.5% 	-1.5% 	2,258 	2,138 5.6% 	8.0% -2.4%
ORAL CARE
US 	173 	170 	1.7% 	1.7% 	- 	332 	313 6.2% 	6.2% 	-
Intl 	225 	224 	0.3% 	3.4% 	-3.1% 	427 	447 -4.7% 	-0.3% -4.4%
WW 	398 	394 	0.9% 	2.7% 	-1.8% 	759 	760 -0.2% 	2.4% -2.6%
BABY CARE
US 	99 	88 	12.5% 	12.5% 	- 	195 	173 12.7% 	12.7% 	-
Intl 	261 	287 	-9.1% 	-4.0% 	-5.1% 	524 	557 -6.0% 	0.1% -6.1%
WW 	360 	375 	-4.0% 	-0.2% 	-3.8% 	719 	730 -1.6% 	3.1% -4.7%
WOMEN'S HEALTH
US 	4 	3 	-2.1% 	-2.1% 	- 	7 	7 -0.1% 	-0.1% 	-
Intl 	235 	228 	3.5% 	10.2% 	-6.7% 	449 	452 -0.7% 	7.2% -7.9%
WW 	238 	230 	3.4% 	10.0% 	-6.6% 	455 	458 -0.6% 	7.1% -7.7%
WOUND CARE / OTHER
US 	149 	133 	12.3% 	12.3% 	- 	264 	245 7.9% 	7.9% 	-
Intl 	58 	65 	-10.3% 	-4.6% 	-5.7% 	107 	117 -8.4% 	-1.5% -6.9%
WW 	207 	197 	4.9% 	6.8% 	-1.9% 	371 	361 2.6% 	4.9% -2.3%
TOTAL CONSUMER HEALTH
US 	1,787 	1,687 	6.0% 	6.0% 	- 	3,522 	3,244 8.6% 	8.6% 	-
Intl 	2,224 	2,118 	5.0% 	9.0% 	-4.0% 	4,341 	4,147 4.7% 	10.1% -5.4%
WW 	4,011	$ 	3,805 	5.4% 	7.7% 	-2.3% 	7,863	$ 	7,391 6.4% 	9.5% -3.1%
See footnotes at end of schedule
% Change 	% Change

-- 15 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
PHARMACEUTICAL SEGMENT (2,3) 	2023 	2022 	Reported Operational (1) Currency 	2023 	2022 Reported Operational (1) Currency
IMMUNOLOGY
US 	2,865	$ 	2,853 	0.4% 	0.4% 	- 	5,313	$ 	5,354 -0.8% 	-0.8% 	-
Intl 	1,631 	1,559 	4.7% 	6.6% 	-1.9% 	3,295 	3,176 3.8% 	8.2% -4.4%
WW 	4,496 	4,411 	1.9% 	2.6% 	-0.7% 	8,608 	8,530 0.9% 	2.6% -1.7%
REMICADE
US 	277 	391 	-29.3% 	-29.3% 	- 	553 	749 -26.2% 	-26.2% 	-
US Exports (4) 	33 	44 	-24.9% 	-24.9% 	- 	74 	124 -40.3% 	-40.3% 	-
Intl 	152 	212 	-28.2% 	-25.2% 	-3.0% 	322 	437 -26.2% 	-22.5% -3.7%
WW 	462 	647 	-28.6% 	-27.6% 	-1.0% 	949 	1,310 -27.5% 	-26.3% -1.2%
SIMPONI / SIMPONI ARIA
US 	285 	301 	-5.1% 	-5.1% 	- 	556 	588 -5.4% 	-5.4% 	-
Intl 	244 	266 	-8.2% 	-4.3% 	-3.9% 	510 	549 -7.1% 	-1.1% -6.0%
WW 	529 	566 	-6.6% 	-4.7% 	-1.9% 	1,066 	1,137 -6.2% 	-3.3% -2.9%
STELARA
US 	1,817 	1,731 	4.9% 	4.9% 	- 	3,268 	3,110 5.1% 	5.1% 	-
Intl 	981 	868 	13.0% 	14.1% 	-1.1% 	1,974 	1,777 11.1% 	15.2% -4.1%
WW 	2,797 	2,599 	7.6% 	8.0% 	-0.4% 	5,241 	4,887 7.2% 	8.7% -1.5%
TREMFYA
US 	450 	382 	17.8% 	17.8% 	- 	856 	773 10.7% 	10.7% 	-
Intl 	255 	214 	19.4% 	21.0% 	-1.6% 	489 	413 18.4% 	22.8% -4.4%
WW 	706 	597 	18.3% 	18.9% 	-0.6% 	1,346 	1,187 13.4% 	15.0% -1.6%
OTHER IMMUNOLOGY
US 	4 	3 	17.8% 	17.8% 	- 	7 	9 -30.2% 	-30.2% 	-
Intl 	0 	0 	- 	- 	- 	0 	0 - 	- 	-
WW 	4 	3 	17.8% 	17.8% 	- 	7 	9 -30.2% 	-30.2% 	-
INFECTIOUS DISEASES
US 	395 	415 	-4.9% 	-4.9% 	- 	787 	876 -10.2% 	-10.2% 	-
Intl 	727 	901 	-19.4% 	-22.0% 	2.6% 	1,920 	1,737 10.5% 	12.3% -1.8%
WW 	1,121 	1,316 	-14.8% 	-16.6% 	1.8% 	2,707 	2,613 3.6% 	4.7% -1.1%
COVID-19 VACCINE
US 	- 	45 	* 	* 	- 	- 	120 	* 	* 	-
Intl 	285 	499 	-43.0% 	-47.4% 	4.4% 	1,032 	881 17.1% 	18.4% -1.3%
WW 	285 	544 	-47.7% 	-51.8% 	4.1% 	1,032 	1,001 3.0% 	4.2% -1.2%
EDURANT / rilpivirine
US 	8 	9 	-9.0% 	-9.0% 	- 	17 	18 -5.3% 	-5.3% 	-
Intl 	258 	215 	19.9% 	17.3% 	2.6% 	529 	454 16.4% 	18.0% -1.6%
WW 	266 	225 	18.6% 	16.2% 	2.4% 	546 	473 15.6% 	17.1% -1.5%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	382 	355 	7.6% 	7.6% 	- 	760 	724 5.0% 	5.0% 	-
Intl 	109 	110 	-0.2% 	-1.0% 	0.8% 	208 	242 -13.9% 	-12.1% -1.8%
WW 	491 	464 	5.8% 	5.6% 	0.2% 	968 	965 0.3% 	0.7% -0.4%
OTHER INFECTIOUS DISEASES
US 	5 	6 	-27.2% 	-27.2% 	- 	10 	14 -30.6% 	-30.6% 	-
Intl 	74 	77 	-3.5% 	3.6% 	-7.1% 	151 	160 -5.6% 	-1.2% -4.4%
WW 	79 	83 	-5.2% 	1.3% 	-6.5% 	161 	174 -7.6% 	-3.6% -4.0%
% Change 	% Change

-- 16 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 Reported Operational (1) Currency
NEUROSCIENCE
US 	1,029 	896 	14.9% 	14.9% 	- 	2,007 	1,739 15.4% 	15.4% 	-
Intl 	764 	837 	-8.8% 	-4.6% 	-4.2% 	1,590 	1,735 -8.4% 	-3.8% -4.6%
WW 	1,793 	1,734 	3.5% 	5.5% 	-2.0% 	3,597 	3,475 3.5% 	5.8% -2.3%
CONCERTA / Methylphenidate
US 	64 	38 	68.2% 	68.2% 	- 	134 	73 84.0% 	84.0% 	-
Intl 	143 	123 	16.3% 	21.3% 	-5.0% 	279 	245 13.9% 	20.7% -6.8%
WW 	208 	161 	28.6% 	32.4% 	-3.8% 	414 	318 30.0% 	35.3% -5.3%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	721 	691 	4.3% 	4.3% 	- 	1,434 	1,352 6.0% 	6.0% 	-
Intl 	310 	362 	-14.4% 	-12.6% 	-1.8% 	641 	749 -14.5% 	-10.7% -3.8%
WW 	1,031 	1,054 	-2.1% 	-1.5% 	-0.6% 	2,075 	2,102 -1.3% 	0.1% -1.4%
SPRAVATO
US 	144 	74 	93.2% 	93.2% 	- 	255 	135 88.3% 	88.3% 	-
Intl 	25 	11 	* 	* 	* 	45 	20 	* 	* 	*
WW 	169 	85 	98.2% 	98.5% 	-0.3% 	300 	155 93.1% 	93.8% -0.7%
OTHER NEUROSCIENCE
US 	100 	93 	9.3% 	9.3% 	- 	184 	179 3.1% 	3.1% 	-
Intl 	286 	341 	-16.4% 	-9.9% 	-6.5% 	625 	721 -13.4% 	-8.7% -4.7%
WW 	386 	433 	-10.9% 	-5.8% 	-5.1% 	809 	900 -10.1% 	-6.4% -3.7%
ONCOLOGY
US 	2,069 	1,679 	23.2% 	23.2% 	- 	3,958 	3,261 21.4% 	21.4% 	-
Intl 	2,329 	2,362 	-1.4% 	0.1% 	-1.5% 	4,552 	4,731 -3.8% 	0.0% -3.8%
WW 	4,398 	4,042 	8.8% 	9.7% 	-0.9% 	8,510 	7,992 6.5% 	8.8% -2.3%
CARVYKTI
US 	114 	24 	* 	* 	- 	184 	24 	* 	* 	-
Intl 	3 	- 	* 	* 	* 	5 	- 	* 	* 	*
WW 	117 	24 	* 	* 	* 	189 	24 	* 	* 	*
DARZALEX
US 	1,322 	1,021 	29.5% 	29.5% 	- 	2,513 	1,974 27.3% 	27.3% 	-
Intl 	1,110 	965 	15.0% 	17.0% 	-2.0% 	2,182 	1,868 16.8% 	21.5% -4.7%
WW 	2,431 	1,986 	22.4% 	23.4% 	-1.0% 	4,695 	3,842 22.2% 	24.5% -2.3%
ERLEADA
US 	241 	233 	3.6% 	3.6% 	- 	490 	439 11.8% 	11.8% 	-
Intl 	326 	218 	49.7% 	51.7% 	-2.0% 	619 	412 50.3% 	55.9% -5.6%
WW 	567 	450 	25.9% 	26.9% 	-1.0% 	1,109 	850 30.4% 	33.2% -2.8%
IMBRUVICA
US 	262 	349 	-24.9% 	-24.9% 	- 	532 	719 -26.0% 	-26.0% 	-
Intl 	579 	620 	-6.7% 	-5.7% 	-1.0% 	1,136 	1,288 -11.8% 	-8.8% -3.0%
WW 	841 	970 	-13.2% 	-12.6% 	-0.6% 	1,668 	2,008 -16.9% 	-15.0% -1.9%
ZYTIGA / abiraterone acetate
US 	9 	19 	-55.2% 	-55.2% 	- 	25 	38 -34.7% 	-34.7% 	-
Intl 	218 	486 	-55.1% 	-53.8% 	-1.3% 	447 	1,006 -55.6% 	-53.0% -2.6%
WW 	227 	505 	-55.1% 	-53.8% 	-1.3% 	472 	1,044 -54.8% 	-52.3% -2.5%
OTHER ONCOLOGY
US 	122 	33 	* 	* 	- 	214 	67 	* 	* 	-
Intl 	92 	72 	27.8% 	29.4% 	-1.6% 	162 	156 3.6% 	7.1% -3.5%
WW 	214 	106 	* 	* 	* 	376 	224 68.0% 	70.4% -2.4%
% Change 	% Change

-- 17 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 	684 	560 	22.0% 	22.0% 	- 	1,284 	1,132 13.4% 	13.4% 	-
Intl 	289 	284 	2.0% 	5.7% 	-3.7% 	561 	563 -0.4% 	5.5% -5.9%
WW 	972 	843 	15.3% 	16.5% 	-1.2% 	1,844 	1,695 8.8% 	10.8% -2.0%
OPSUMIT
US 	328 	265 	23.7% 	23.7% 	- 	601 	538 11.6% 	11.6% 	-
Intl 	179 	173 	3.4% 	6.0% 	-2.6% 	346 	343 0.9% 	6.1% -5.2%
WW 	507 	438 	15.7% 	16.7% 	-1.0% 	947 	881 7.5% 	9.5% -2.0%
UPTRAVI
US 	338 	272 	24.2% 	24.2% 	- 	642 	541 18.7% 	18.7% 	-
Intl 	61 	56 	10.0% 	14.1% 	-4.1% 	119 	112 6.6% 	11.7% -5.1%
WW 	399 	328 	21.8% 	22.5% 	-0.7% 	761 	653 16.6% 	17.5% -0.9%
OTHER PULMONARY HYPERTENSION
US 	18 	23 	-23.8% 	-23.8% 	- 	41 	53 -23.0% 	-23.0% 	-
Intl 	48 	55 	-10.9% 	-3.7% 	-7.2% 	95 	108 -11.7% 	-2.8% -8.9%
WW 	66 	78 	-14.7% 	-9.7% 	-5.0% 	136 	161 -15.5% 	-9.5% -6.0%
CARDIOVASCULAR / METABOLISM / OTHER
US 	776 	757 	2.6% 	2.6% 	- 	1,491 	1,429 4.3% 	4.3% 	-
Intl 	174 	215 	-19.0% 	-18.3% 	-0.7% 	386 	453 -14.7% 	-12.0% -2.7%
WW 	950 	972 	-2.2% 	-2.0% 	-0.2% 	1,877 	1,882 -0.3% 	0.4% -0.7%
XARELTO
US 	637 	609 	4.7% 	4.7% 	- 	1,215 	1,117 8.8% 	8.8% 	-
Intl 	- 	- 	- 	- 	- 	- 	- - 	- 	-
WW 	637 	609 	4.7% 	4.7% 	- 	1,215 	1,117 8.8% 	8.8% 	-
OTHER
US 	138 	148 	-6.3% 	-6.3% 	- 	275 	312 -11.8% 	-11.8% 	-
Intl 	174 	215 	-19.0% 	-18.3% 	-0.7% 	386 	453 -14.7% 	-12.0% -2.7%
WW 	313 	363 	-13.8% 	-13.4% 	-0.4% 	662 	765 -13.5% 	-11.9% -1.6%
TOTAL PHARMACEUTICAL
US 	7,818 	7,159 	9.2% 	9.2% 	- 	14,841 	13,791 7.6% 	7.6% 	-
Intl 	5,913 	6,158 	-4.0% 	-2.5% 	-1.5% 	12,303 	12,395 -0.7% 	3.1% -3.8%
WW 	13,731	$ 	13,317 	3.1% 	3.8% 	-0.7% 	27,144	$ 	26,186 3.7% 	5.5% -1.8%
See footnotes at end of schedule
% Change 	% Change

-- 18 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
MEDTECH SEGMENT (2,3) 	2023 	2022 	Reported Operational (1) Currency 	2023 	2022 Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	908	$ 	525 	73.1% 	73.1% 	- 	1,771	$ 	1,019 73.8% 	73.8% 	-
Intl 	712 	525 	35.7% 	40.7% 	-5.0% 	1,352 	1,123 20.5% 	27.0% -6.5%
WW 	1,620 	1,049 	54.4% 	56.9% 	-2.5% 	3,123 	2,141 45.8% 	49.3% -3.5%
ELECTROPHYSIOLOGY
US 	609 	499 	22.0% 	22.0% 	- 	1,180 	969 21.7% 	21.7% 	-
Intl 	587 	469 	25.1% 	30.0% 	-4.9% 	1,109 	1,001 10.8% 	17.3% -6.5%
WW 	1,196 	968 	23.5% 	25.9% 	-2.4% 	2,288 	1,970 16.2% 	19.5% -3.3%
ABIOMED
US 	272 	- 	* 	* 	- 	536 	- 	* 	* 	-
Intl 	59 	- 	* 	* 	* 	119 	- 	* 	* 	*
WW 	331 	- 	* 	* 	* 	655 	- 	* 	* 	*
OTHER INTERVENTIONAL SOLUTIONS
US 	27 	26 	4.5% 	4.5% 	- 	55 	50 10.8% 	10.8% 	-
Intl 	67 	56 	20.0% 	25.3% 	-5.3% 	125 	121 2.8% 	8.9% -6.1%
WW 	93 	81 	15.1% 	18.8% 	-3.7% 	180 	171 5.1% 	9.5% -4.4%
ORTHOPAEDICS
US 	1,388 	1,338 	3.7% 	3.7% 	- 	2,751 	2,627 4.7% 	4.7% 	-
Intl 	878 	820 	7.0% 	9.0% 	-2.0% 	1,759 	1,719 2.3% 	6.4% -4.1%
WW 	2,265 	2,157 	5.0% 	5.7% 	-0.7% 	4,510 	4,345 3.8% 	5.4% -1.6%
HIPS
US 	250 	240 	4.1% 	4.1% 	- 	491 	465 5.6% 	5.6% 	-
Intl 	147 	148 	-0.8% 	1.2% 	-2.0% 	296 	312 -5.1% 	-1.3% -3.8%
WW 	397 	388 	2.2% 	3.0% 	-0.8% 	787 	777 1.3% 	2.8% -1.5%
KNEES
US 	221 	216 	2.4% 	2.4% 	- 	447 	417 7.2% 	7.2% 	-
Intl 	142 	133 	6.3% 	8.0% 	-1.7% 	284 	271 4.8% 	8.8% -4.0%
WW 	363 	349 	3.9% 	4.5% 	-0.6% 	731 	688 6.3% 	7.9% -1.6%
TRAUMA
US 	483 	464 	4.3% 	4.3% 	- 	974 	939 3.7% 	3.7% 	-
Intl 	255 	232 	9.9% 	10.9% 	-1.0% 	522 	505 3.2% 	7.0% -3.8%
WW 	739 	696 	6.1% 	6.5% 	-0.4% 	1,496 	1,444 3.6% 	4.9% -1.3%
SPINE, SPORTS & OTHER
US 	433 	418 	3.5% 	3.5% 	- 	839 	805 4.1% 	4.1% 	-
Intl 	334 	306 	9.0% 	11.6% 	-2.6% 	657 	630 4.2% 	8.7% -4.5%
WW 	766 	724 	5.8% 	7.0% 	-1.2% 	1,495 	1,436 4.2% 	6.1% -1.9%
% Change 	% Change

-- 19 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 Reported Operational (1) Currency
SURGERY
US 	1,015 	992 	2.2% 	2.2% 	- 	1,990 	1,913 4.0% 	4.0% 	-
Intl 	1,580 	1,458 	8.4% 	12.6% 	-4.2% 	3,039 	2,971 2.3% 	7.7% -5.4%
WW 	2,594 	2,450 	5.9% 	8.4% 	-2.5% 	5,028 	4,884 3.0% 	6.3% -3.3%
ADVANCED
US 	466 	454 	2.7% 	2.7% 	- 	910 	871 4.5% 	4.5% 	-
Intl 	757 	702 	7.8% 	12.1% 	-4.3% 	1,430 	1,431 0.0% 	5.3% -5.3%
WW 	1,222 	1,156 	5.8% 	8.4% 	-2.6% 	2,340 	2,302 1.7% 	5.0% -3.3%
GENERAL
US 	548 	538 	1.9% 	1.9% 	- 	1,079 	1,042 3.6% 	3.6% 	-
Intl 	823 	756 	8.9% 	13.1% 	-4.2% 	1,608 	1,540 4.5% 	10.0% -5.5%
WW 	1,372 	1,294 	6.0% 	8.4% 	-2.4% 	2,688 	2,582 4.1% 	7.4% -3.3%
VISION
US 	529 	496 	6.6% 	6.6% 	- 	1,087 	1,017 6.9% 	6.9% 	-
Intl 	778 	745 	4.6% 	7.1% 	-2.5% 	1,521 	1,481 2.7% 	7.5% -4.8%
WW 	1,308 	1,241 	5.4% 	6.9% 	-1.5% 	2,608 	2,498 4.4% 	7.2% -2.8%
CONTACT LENSES / OTHER
US 	409 	374 	9.1% 	9.1% 	- 	853 	774 10.1% 	10.1% 	-
Intl 	530 	519 	2.2% 	4.8% 	-2.6% 	1,039 	1,030 0.9% 	6.3% -5.4%
WW 	939 	894 	5.1% 	6.6% 	-1.5% 	1,892 	1,804 4.9% 	8.0% -3.1%
SURGICAL
US 	120 	122 	-1.1% 	-1.1% 	- 	234 	243 -3.6% 	-3.6% 	-
Intl 	249 	225 	10.1% 	12.3% 	-2.2% 	482 	451 6.7% 	10.2% -3.5%
WW 	369 	347 	6.2% 	7.6% 	-1.4% 	716 	694 3.1% 	5.4% -2.3%
TOTAL MEDTECH
US 	3,839 	3,351 	14.6% 	14.6% 	- 	7,598 	6,576 15.5% 	15.5% 	-
Intl 	3,949 	3,547 	11.3% 	14.7% 	-3.4% 	7,671 	7,293 5.2% 	10.3% -5.1%
WW 	7,788	$ 	6,898 	12.9% 	14.7% 	-1.8% 	15,269	$ 	13,869 10.1% 	12.8% -2.7%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change 	% Change

-- 20 of 24 --

2023 	2022 	Total 	Operations Currency 	2023 	2022 	Total 	Operations Currency
Pharmaceutical
U.S. 	7,818	$ 	7,159 	9.2 % 	9.2 	- 	14,841	$ 	13,791 	7.6 % 	7.6 	-
International 	5,913 	6,158 	(4.0) 	(2.5) 	(1.5) 	12,303 	12,395 	(0.7) 	3.1 	(3.8)
Worldwide 	13,731 	13,317 	3.1 	3.8 	(0.7) 	27,144 	26,186 	3.7 	5.5 	(1.8)
COVID-19 Vaccine
U.S. 	- 	45 	* 	* 	- 	- 	120 	* 	* 	-
International 	285 	499 	(43.0) 	(47.4) 	4.4 	1,032 	881 	17.1 	18.4 	(1.3)
Worldwide 	285 	544 	(47.7) 	(51.8) 	4.1 	1,032 	1,001 	3.0 	4.2 	(1.2)
Pharmaceutical excluding COVID-19 Vaccine
U.S. 	7,818 	7,114 	9.9 	9.9 	- 	14,841 	13,671 	8.6 	8.6 	-
International 	5,628 	5,659 	(0.5) 	1.5 	(2.0) 	11,271 	11,514 	(2.1) 	1.9 	(4.0)
Worldwide 	13,446 	12,773 	5.3 	6.2 	(0.9) 	26,112 	25,185 	3.7 	5.5 	(1.8)
Worldwide
U.S. 	13,444 	12,197 	10.2 	10.2 	- 	25,961 	23,611 	10.0 	10.0 	-
International 	12,086 	11,823 	2.2 	4.7 	(2.5) 	24,315 	23,835 	2.0 	6.5 	(4.5)
Worldwide 	25,530 	24,020 	6.3 	7.5 	(1.2) 	50,276 	47,446 	6.0 	8.2 	(2.2)
COVID-19 Vaccine
U.S. 	- 	45 	* 	* 	- 	- 	120 	* 	* 	-
International 	285 	499 	(43.0) 	(47.4) 	4.4 	1,032 	881 	17.1 	18.4 	(1.3)
Worldwide 	285 	544 	(47.7) 	(51.8) 	4.1 	1,032 	1,001 	3.0 	4.2 	(1.2)
Worldwide
U.S. 	13,444 	12,152 	10.6 	10.6 	- 	25,961 	23,491 	10.5 	10.5 	-
International 	11,801 	11,324 	4.2 	7.0 	(2.8) 	23,283 	22,954 	1.4 	6.1 	(4.7)
Worldwide excluding COVID-19 Vaccine 	25,245	$ 	23,476 	7.5 % 	8.9 	(1.4) 	49,244	$ 	46,445 	6.0 % 	8.3 	(2.3)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
SECOND QUARTER 	SIX MONTHS
Percent Change 	Percent Change

-- 21 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment 	$ 	860 	784 	4,862 	4,420 	1,699 	1,141 	(377) 	(237) 	(282) 	(268) 	6,762 	5,840
% to Sales 	21.4% 	20.6% 	35.4% 	33.2% 	21.8% 	16.5% 	-1.5% 	-1.0% 	-1.1% 	-1.1% 	26.5% 	24.3%
Intangible asset amortization expense 	81 	100 	748 	736 	382 	259 	- 	- 	- 	- 	1,211 	1,095
In-process research and development 	- 	- 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Litigation related 	- 	78 	(93) 	36 	60 	271 	170 	- 	- 	- 	137 	385
COVID-19 Vaccine related costs 	- 	- 	165 	276 	- 	- 	- 	- 	- 	- 	165 	276
Loss/(gain) on securities 	- 	- 	38 	102 	(39) 	7 	- 	- 	- 	- 	(1) 	109
Restructuring related 	- 	25 	145 	23 	- 	80 	- 	- 	- 	- 	145 	128
Acquisition, integration and divestiture related 	- 	- 	- 	- 	38 	- 	- 	- 	- 	- 	38 	-
Medical Device Regulation 	- 	- 	- 	- 	85 	70 	- 	- 	- 	- 	85 	70
Consumer Health separation costs 	- 	- 	- 	- 	- 	- 	- 	- 	282 	268 	282 	268
-
Other 	- 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Adjusted Income Before Tax by Segment 	$ 	941 	987 	5,865 	5,593 	2,225 	1,828 	(207) 	(237) 	- 	- 	8,824 	8,171
% to Sales 	23.5% 	25.9% 	42.7% 	42.0% 	28.6% 	26.5% 	-0.8% 	-1.0% 	0.0% 	0.0% 	34.6% 	34.0%
*Estimated as of 7/20/2023
Q2 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health 	Pharmaceutical 	MedTech 	Unallocated 	Worldwide Total

-- 22 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment 	$ 1,636 	1,470 	9,306 	8,344 	3,144 	2,618 	(7,479) 	(360) 	(582) 	(370) 	6,025 	11,702
% to Sales 	20.8% 	19.9% 	34.3% 	31.9% 	20.6% 	18.9% 	-14.9% 	-0.8% 	-1.2% 	-0.8% 	12.0% 	24.7%
Intangible asset amortization expense 	163 	194 	1,487 	1,496 	765 	513 	- 	- 	- 	- 	2,415 	2,203
In-process research and development 	- 	- 	- 	610 	49 	- 	- 	- 	- 	- 	49 	610
Litigation related 	- 	78 	(93) 	36 	60 	271 	7,070 	- 	- 	- 	7,037 	385
COVID-19 Vaccine related costs 	- 	- 	609 	276 	- 	- 	- 	- 	- 	- 	609 	276
Loss/(gain) on securities 	- 	- 	76 	496 	(5) 	24 	- 	- 	- 	- 	71 	520
Restructuring related 	- 	39 	275 	9 	- 	152 	- 	- 	- 	- 	275 	200
Acquisition, integration and divestiture related 	- 	- 	- 	- 	80 	- 	- 	- 	- 	- 	80 	-
Medical Device Regulation 	- 	- 	- 	- 	149 	130 	- 	- 	- 	- 	149 	130
Consumer Health separation costs 	- 	- 	- 	- 	- 	- 	- 	- 	582 	370 	582 	370
Other 	- 	- 	- 	- 	- 	- 	- 	(7) 	- 	- 	- 	(7)
Adjusted Income Before Tax by Segment 	$ 1,799 	1,781 	11,660 	11,267 	4,242 	3,708 	(409) 	(367) 	- 	- 	17,292 	16,389
% to Sales 	22.9% 	24.1% 	43.0% 	43.0% 	27.8% 	26.7% 	-0.8% 	-0.8% 	0.0% 	0.0% 	34.4% 	34.5%
*Estimated as of 7/20/2023
Q2 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health 	Pharmaceutical 	MedTech 	Unallocated 	Worldwide Total

-- 23 of 24 --

Second Quarter 	Second Quarter
July 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
July 3, 2022
Non-GAAP
Cost of products sold 	8,212	$ 	(1,211) 	- 	(34) 	38 	(14) 	- 	- 	- 	6,991
Selling, marketing and admin expenses 	6,665 	(8) 	(44) 	6,613
Research and development expense 	3,829 	- 	(44) 	(46) 	(2) 	3,737
Other (Income) / Expense 	(60) 	- 	(137) 	- 	(38) 	1 	(156) 	(221) 	- 	- 	(611)
In-process research and development 	- 	- 	-
Interest (Income)/Expense 	(23) 	(1) 	(24)
Restructuring 	145 	(145) 	-
Provision for taxes on income 	1,618 	194 	29 	- 	37 	12 	(1) 	15 	38 	49 	(546) 	21 	- 	1,466
Net Earnings 	5,144 	1,017 	108 	- 	108 	26 	- 	71 	126 	233 	546 	(21) 	- 	7,358
Second Quarter 	Second Quarter
July 3, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
July 3, 2022
Non-GAAP
Cost of products sold 	7,919	$ 	(1,083) 	(17) 	(25) 	(194) 	- 	- 	- 	- 	6,600
Selling, marketing and admin expenses 	6,226 	(6) 	6,220
Research and development expense 	3,703 	- 	(39) 	(110) 	3,554
Other (Income) / Expense 	273 	(12) 	(385) 	(26) 	- 	(109) 	28 	(268) 	- 	- 	(499)
In-process research and development 	- 	- 	-
Restructuring 	85 	(85) 	-
Provision for taxes on income 	1,026 	170 	(29) 	- 	25 	- 	25 	13 	65 	44 	(2) 	(78) 	- 	1,259
Net Earnings 	4,814 	925 	414 	- 	103 	- 	84 	57 	211 	224 	2 	78 	- 	6,912
Six Months 	Six Months
July 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
July 2, 2023
Non-GAAP
Cost of products sold 	16,607	$ 	(2,411) 	- 	(57) 	(168) 	(26) 	13,945
Selling, marketing and admin expenses 	12,803 	(15) 	(82) 	12,706
Research and development expense 	7,392 	(16) 	(78) 	(62) 	(4) 	7,232
Other (Income) / Expense 	7,168 	(4) 	(7,037) 	- 	(64) 	(71) 	(378) 	(506) 	- 	- 	(892)
In-process research and development 	49 	(49) 	- 	- 	-
Interest (Income)/Expense 	(43) 	36 	(7)
Restructuring 	275 	(275) 	-
Provision for taxes on income 	949 	388 	1,651 	11 	69 	17 	15 	27 	143 	109 	(557) 	44 	- 	2,866
Net Earnings 	5,076 	2,027 	5,386 	38 	206 	63 	56 	123 	465 	473 	557 	(44) 	- 	14,426
Six Months 	Six Months
July 3, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
July 3, 2022
Non-GAAP
Cost of products sold 	15,517	$ 	(2,191) 	(33) 	(47) 	(194) 	13,052
Selling, marketing and admin expenses 	12,164 	(12) 	12,152
Research and development expense 	7,165 	- 	(71) 	(110) 	6,984
Other (Income) / Expense 	171 	(12) 	(385) 	(12) 	- 	(520) 	28 	(370) 	- 	7 	(1,093)
In-process research and development 	610 	(610) 	-
Restructuring 	155 	(155) 	-
Provision for taxes on income 	1,739 	338 	(82) 	138 	37 	- 	121 	24 	65 	67 	(98) 	1 	(2) 	2,348
Net Earnings 	9,963 	1,865 	467 	472 	163 	- 	399 	106 	211 	303 	98 	(1) 	(5) 	14,041
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Year to Date
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs

-- 24 of 24 --